To print this article, all you need is to be registered or login on Mondaq.com.
CASE LAW DEVELOPMENTS
A Pharmaceutical Conflict over an ICC Award Is Building
Momentum
The Taiwanese company PharmaEssentia is trying to challenge an
ICC award issued in a dispute with its Austrian counterparty. The
dispute arose over a license agreement for the development and
commercialization of a leukemia drug.
In October 2020, the ICC tribunal ruled in favor of the Austrian
company AOP Orphan Pharmaceuticals, awarding it EUR 2 billion. The
dispute resulted from PharmaEssentia s attempt to terminate a
license agreement, under which it undertook to provide to AOP